Vident Advisory, LLC Pacira Bio Sciences, Inc. Transaction History
Vident Advisory, LLC
- $5.7 Trillion
- Q4 2024
A detailed history of Vident Advisory, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 29,354 shares of PCRX stock, worth $746,765. This represents 0.01% of its overall portfolio holdings.
Number of Shares
29,354
Previous 30,847
4.84%
Holding current value
$746,765
Previous $464 Million
19.12%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding PCRX
# of Institutions
259Shares Held
49.7MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$204 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$134 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$83 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$57.4 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$50.7 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.17B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...